Adverum Biotechnologies, Inc. (ADVM): Price and Financial Metrics


Adverum Biotechnologies, Inc. (ADVM): $0.69

0.03 (+4.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADVM to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ADVM Stock Price Chart Interactive Chart >

Price chart for ADVM

ADVM Price/Volume Stats

Current price $0.69 52-week high $1.82
Prev. close $0.67 52-week low $0.53
Day low $0.65 Volume 233,000
Day high $0.70 Avg. volume 244,178
50-day MA $0.65 Dividend yield N/A
200-day MA $1.00 Market Cap 69.24M

Adverum Biotechnologies, Inc. (ADVM) Company Bio


Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company was founded in 2006 and is based in Menlo Park, California.


ADVM Latest News Stream


Event/Time News Detail
Loading, please wait...

ADVM Latest Social Stream


Loading social stream, please wait...

View Full ADVM Social Stream

Latest ADVM News From Around the Web

Below are the latest news stories about ADVERUM BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate ADVM as an investment opportunity.

Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee. On December 1, 2022, Adverum granted a new employee a stock option to purchase 200,000 shares of Adverum’s common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is m

Yahoo | December 6, 2022

Adverum Biotechnologies Reports Third Quarter 2022 Financial Results

- First subject dosed in our Phase 2 LUNA trial with Ixo-vec (ixoberogene soroparvovec, formerly referred to as ADVM-022) and anticipate preliminary data throughout 2023 - Cash runway into 2025 prioritizing Ixo-vec clinical development in wet age-related macular degeneration (wet AMD) REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocul

Yahoo | November 10, 2022

Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)

- Data demonstrating that Ixo-vec was generally well tolerated and that a single intravitreal (IVT) injection can lead to stable and persistent aflibercept protein levels through three years in participants in the OPTIC extension study - 81% – 98% reduction in mean annualized anti-VEGF injections after a single IVT injection of Ixo-vec, including 80% and 53% of participants supplemental injection free over two years across the 6x10^11 (6E11) and 2x10^11 (2E11) doses, respectively, regardless of

Yahoo | November 4, 2022

Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting

REDWOOD CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that new data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week at The Retina Society Annual Meeting in Pasadena, California. End of stu

Yahoo | October 27, 2022

Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD

- New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision outcomes, as well as decreasing treatment burden by an 81-98% reduction in mean annualized anti-VEGF injections - The 2x10^11 vg/eye (2E11) dose meaningfully reduced fluid volume, including a 93% reduction in intraretinal (IRF) and 55% reduction in subretinal fluid (SRF) from baseline to week 48 -

Yahoo | September 30, 2022

Read More 'ADVM' Stories Here

ADVM Price Returns

1-mo 25.02%
3-mo -23.77%
6-mo -52.74%
1-year -54.00%
3-year -93.53%
5-year -90.14%
YTD 19.07%
2022 -67.07%
2021 -83.76%
2020 -5.90%
2019 265.71%
2018 -10.00%

Continue Researching ADVM

Here are a few links from around the web to help you further your research on Adverum Biotechnologies Inc's stock as an investment opportunity:

Adverum Biotechnologies Inc (ADVM) Stock Price | Nasdaq
Adverum Biotechnologies Inc (ADVM) Stock Quote, History and News - Yahoo Finance
Adverum Biotechnologies Inc (ADVM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6456 seconds.